http://www.fpnotebook.com/
Rheumatoid Arthritis Management
- See Also
- Approach
- Assess Current disease activity
- Morning Stiffness
- Synovitis
- Fatigue
- Erythrocyte Sedimentation Rate
- Document Joint Damage
- Joint Range of motion and deformities
- XRay joint space narrowing and Erosions
- Functional status
- Document Joint Extra-articular manifestations
- Nodules
- Pulmonary fibrosis
- Vasculitis
- Assess Current disease activity
- Management
- Non-Pharmacologic
- Systemic and articular rest
- Physiotherapy (heat, cold)
- Exercises
- Range of Motion
- Conditioning
- Strengthening Exercises
- Assistive Devices
- Patient Education Materials
- Arthritis Foundation
- American College Rheumatology
- Rheumatoid Arthritis Remittive Medications (DMARDs)
- Most important agents in Rheumatoid Arthritis
- Examples: Methotrexate, Sulfasalazine, Plaquenil
- Rheumatoid Arthritis Antiinflammatory Medications
- Used in combination with DMARDs
- Example: NSAIDs, COX2 Inhibitors
- Other medications
- Atorvastatin
- Showed modest benefit in clinical improvement
- McCarey (2004) Lancet 363:2015
- Atorvastatin
- Non-Pharmacologic
Rheumatoid Arthritis (C0003873) | |
|---|---|
| Definition (MSH) | A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. |
| Definition (CSP) | chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures; etiology is unknown, but autoimmune mechanisms have been implicated. |
| Definition (NCI) | A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. |
| Concepts | Disease or Syndrome (T047) |
| ICD9 | 714.0, 714.0 |
| MSH | D001172 |
| English | ARTHRITIS RHEUMATOID, Atrophic arthritis, Chronic rheumatic arthritis, RA, RA - Rheumatoid arthritis, RhA - Rheumatoid arthritis, Rheumatic gout, Rheumatoid Arthritis, Rheumatoid disease |
| Spanish | artritis atrofica, artritis reumatica cronica, artritis reumatoide, gota reumatica |
| Parent Concepts | Inflammatory polyarthritis (C1692871), [X]Inflammatory polyarthropathies (C1692324), Arthritis (C0003864), Autoimmune Diseases (C0004364), Arthropathies NOS (C0022408), COLLAGEN VASCULAR DISEASE (C0262428), Multiple Organ Syndromes NEC (C0549513), Rheumatoid arthritis and other inflammatory polyarthropathies (C0157913), Rheumatism (C0035435), Rheumatologic Disorder (C0748408), Rheumatoid Arthritis (C0003873), Arthropathy associated with a hypersensitivity reaction (C0263730), Duplicate concept (C1274013), Delayed hypersensitivity disorder (C1960693) |
| Sources | AIR, AOD, COSTAR, CSP, CST, DXP, ICD9CM, MEDLINEPLUS, MSH, MTH, MTHICD9, NCI, NDFRT, OMIM, QMR, SCTSPA, SNOMEDCT Derived from the NIH UMLS (Unified Medical Language System) |
